Literature DB >> 19921741

Down syndrome: comments and reflections on the 50th anniversary of Lejeune's discovery.

Giovanni Neri1, John M Opitz.   

Abstract

Over the past some 160 years, the study of Down syndrome (DS) went from early efforts of differentiating it from cretinism (Séguin) to its establishment as a specific nosologic category of mental deficiency (Down) and subsequent attempts to infer its cause. DS was known to be an overwhelmingly sporadic disorder, concordant in MZ and discordant in DZ twins and associated with increased maternal reproductive age (Penrose). Beginning in the 1920s and based in part on phenotype analysis and early cytogenetic insights in Drosophilia, several clinicians (Halbertsma, Waardenburg, Bleyer, Fanconi) and the geneticist C.B. Davenport postulated that DS might be due to a chromosome abnormality; only Davenport, with T.S. Painter, made an actual attempt to perform a clinical/cytological study (with inconclusive results). It was only with the application of the methods of Belling (colchicine, squash preparations) and of T.C. Hsu (hypotonic solution) to PHA-treated cell cultures in the mid-late 1950s, that it became possible to study, accurately, the human karyotype and its aberrations, allowing Lejeune et al. and Jacobs et al. in 1959 to discover the cause of DS. Nowadays, aided with powerful molecular methods, it has become possible to attain insights into the pathogenesis of DS based on the study of many duplications/deficiencies of HSA21 in humans and ingeniously constructed cytogenetic rearrangements of MMA16 in the mouse. These suggest a complex epigenetic interaction between genes on HSA21 and many (?most) other genes in the human genome, akin to an attempt at speciation as suggested early during the last century by Blakesly in his work on Datura. Many important ongoing efforts are underway in several countries to understand the developmental biology of DS, offering hope of ultimate amelioration for those averse to pregnancy termination.

Entities:  

Mesh:

Year:  2009        PMID: 19921741     DOI: 10.1002/ajmg.a.33138

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  2 in total

1.  Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes.

Authors:  Jennifer Keck-Wherley; Deepak Grover; Sharmistha Bhattacharyya; Xiufen Xu; Derek Holman; Eric D Lombardini; Ranjana Verma; Roopa Biswas; Zygmunt Galdzicki
Journal:  Dev Neurosci       Date:  2011-10-27       Impact factor: 2.984

2.  Identification of a DNA methylation signature in blood cells from persons with Down Syndrome.

Authors:  Maria Giulia Bacalini; Davide Gentilini; Alessio Boattini; Enrico Giampieri; Chiara Pirazzini; Cristina Giuliani; Elisa Fontanesi; Maria Scurti; Daniel Remondini; Miriam Capri; Guido Cocchi; Alessandro Ghezzo; Alberto Del Rio; Donata Luiselli; Giovanni Vitale; Daniela Mari; Gastone Castellani; Mario Fraga; Anna Maria Di Blasio; Stefano Salvioli; Claudio Franceschi; Paolo Garagnani
Journal:  Aging (Albany NY)       Date:  2015-02       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.